Small observational studies suggest that treatment of T2DM (with or without heart failure) with SGLT-2 inhibitors improves left ventricular filling pressure, as measured by E/e′ ratio and left atrial volume index24,25. Here, SLC5A2 is linked to type 2 diabetes mellitus.